Low Dose Naltexone and Cancer Part 4

Among those who have shown significant movement toward remission, most had never received chemotherapy. The apparent remissions:
2 children with neuroblastoma
6 patients with non-Hodgkin's lymphoma
3 with Hodgkin's disease
5 with pancreatic cancer metastatic to the liver
5 with multiple myeloma
1 with carcinoid
4 with breast cancer metastatic to bone
4 with ovarian cancer
18 with non-small cell cancer of the lung
1 with small cell cancer of the lung
5 with prostate cancer (no prior hormone-blocking therapy)

(Although recently-diagnosed prostate cancer patients who have not received other therapies appear to do well on LDN, patients with prostate cancer who have already been treated with hormone-related therapies, including testosterone-blocking drugs and PC-Spes, have not responded to LDN.)
An overview of these results must assume the basic statistical principle that the patients with no follow-up contact have not done as well as those who have maintained continual medical contact with Dr. Bihari. Measured in terms of disease stabilization and/or movement toward remission, and assuming that patients in continual follow-up are twice as likely to have had a good outcome thus far, it appears that over one-half of all cancer patients whom Dr. Bihari has started on LDN have done well.
Taking into account the relatively large number of patients who were in advanced stages of disease when first seen by Dr. Bihari, and that some patients in the "not followed up" and "LDN < 6 mos" groups will likely have positive outcomes, it appears possible that more than 60% of patients with cancer may significantly benefit from LDN. This is underscored by Dr. Bihari's observation that better outcomes tend to be seen when treatment with LDN is begun in earlier stages of the disease. Of interest, there is a negligible rate of relapse in patients who are started on LDN after or during successful initial treatment with surgery (e.g., for breast cancer) or with chemotherapy (e.g., for Hodgkin's disease or non-Hodgkin's lymphoma).
It will clearly require extensive study of LDN in prospective, controlled clinical trials to determine which cancers respond best and which other therapies are complementary to or synergistic

Source:http://www.lowdosenaltrexone.org

Low Dose Naltexone and Cancer Part 3

Recent Developments
> As of March 2004
Since February 1999, Dr. Bihari has begun treatment of some 450 cancer patients with LDN. Since many of these patients, particularly those seen before October 2000, were seen only once in consultation with medical follow-up by their oncologists, Dr. Bihari is missing up-to-date follow-up data on 96 patients.
As of March 2004, of the remaining 354 patients, 84 have died, all but 4 of cancer-related causes. Most of these deaths have occurred in the first 8 to 12 weeks on LDN. For the most part, these were patients who were quite ill when first seen, and had exhausted all other treatment possibilities. Of the remaining 270 patients, 220 have been on LDN for six months or longer. Of these, 86 have shown significant movement toward remission, identified for this purpose as a reduction of at least 75% in tumor mass and tumor-related symptoms. Of the other 134 patients, 9 have continued to show tumor progression, whereas the other 125 have stabilized and/or are moving toward remission but do not yet meet the 75% reduction criterion.

Low Dose Naltexone and Cancer Part 2

Cancers that are reported by Dr. Bihari to apparently respond to LDN:
Bladder Cancer
Breast Cancer
Carcinoid
Colon & Rectal Cancer
Glioblastoma
Liver Cancer
Lung Cancer (Non-Small Cell)
Lymphocytic Leukemia (chronic)
Lymphoma (Hodgkin's and Non-Hodgkin's) Malignant Melanoma
Multiple Myeloma
Neuroblastoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer (untreated)
Renal Cell Carcinoma
Throat Cancer
Uterine Cancer > What the Future Holds
If the results of trials of low dose naltrexone in certain cancers are positive, the drug could eventually become an additional mainstay of cancer treatment ? adjunctive with chemotherapy, radiation, and other cancer cell growth inhibitor receptor agonists ? or even a replacement for current therapies, as primary treatment for those cancers that show little response to standard therapies.

Low Dose Naltexone and Cancer Part 1

LDN and Cancer
In Brief  Recent Developments  Noteworthy Cases  Background  LDN Homepage

In Brief
Although prospective, controlled clinical trials on LDN in the treatment of cancer are yet to be accomplished, as of March 2004 clinical "off-label" use of this medication by Dr. Bihari in some 450 patients with cancer almost all of whom had failed to respond to standard treatments suggests that more than 60% of patients with cancer may significantly benefit from LDN.
Of the 354 patients with whom Dr. Bihari had regular follow-up, 86 have shown objective signs of significant tumor shrinkage, at least a 75% reduction. 125 patients have stabilized and/or are moving toward remission.
Dr. Bihari's results sharply contrast to prior usual cancer treatment outcomes: either a cancer-induced death or a total cure. LDN therapy presents a viable third alternative, the possible long-term stabilization and/or gradual reduction of tumor mass volume.
Thus, with LDN, cancer can — in some cases — become a manageable chronic disease. Patients have the possibility of living free of symptoms, without, in many cases, the crippling side-effects of chemotherapy and radiation treatment.
> How It Works
Low dose naltrexone might exert its effects on tumor growth through a mix of three possible mechanisms:
1.By inducing increases of metenkephalin (an endorphin produced in large amounts in the adrenal medulla) and beta endorphin in the blood stream;
2.By inducing an increase in the number and density of opiate receptors on the tumor cell membranes, thereby making them more responsive to the growth-inhibiting effects of the already-present levels of endorphins, which induce apoptosis (cell death) in the cancer cells; and
3.By increasing the natural killer (NK) cell numbers and NK cell activity and lymphocyte activated CD8 numbers, which are quite responsive to increased levels of endorphins.

Ellagic Acid Part3

Ellagic Acid Study - The Hollings Cancer Institute at the University of South Carolina has conducted a double blind study on a group of 500 cervical cancer patients that had everyone excited. Nine years of study have shown that a natural product called Ellagic acid is causing G-arrest within 48 hours (inhibiting and stopping mitosis-cancer cell division), and apoptosis (normal cell death) within 72 hours, for breast, pancreas, esophageal, skin, colon and prostate cancer cells.
Ellagic Acid Clinical Tests on cultured human cells also show that Ellagic acid prevents the destruction of the p53 gene by cancer cells. Additional studies suggest that one of the mechanisms by which Ellagic acid inhibits mutagenesis and carcinogenesis is by forming adducts with DNA, thus masking binding sites to be occupied by the mutagen or carcinogen. Ellagic acid can be found in different foods. The Hollings Clinic has identified the red raspberry for their studies."

Ellagic Acid is astounding cancer researchers worldwide with it's ability to apparently prevent many types of cancer cells from multiplying, thus causing the cancer to die. This compound is found in berries.
Experience the synergistic effects of five super fruits (mangosteen, acai, pomegranate, noni, goji) plus resveratrol. Loaded with antioxidants that support higher energy levels and a stronger immune system. Also includes proprietary fruit blend from raspberries, wild cherry, blueberry, elderberry and grapeseed extract.

Source: http://alternativecancer.us